PATIENT ENROLLMENT COMPLETED IN CLINICAL STUDY OF MOB-015

Moberg Pharma AB (OMX: MOB) today announced the completion of patient enrollment
in the ongoing Phase II clinical trial of MOB-015. MOB-015 is a topical
formulation of terbinafine for the treatment of nail fungus (onychomycosis).
The purpose of this study is to confirm the product concept of MOB-015 and
provide a basis for a Phase III study and out-licensing. Patients are treated
for twelve months and followed for a total of fifteen months with respect to the
endpoints that the FDA and EMA normally accept for nail fungus. The study is
conducted with leading expertise in the field at Sahlgrenska University Hospital
in Gothenburg, Sweden.

"MOB-015 has the potential to become a valuable addition to our product
portfolio and we look forward to the outcome of the study during next year,"
said Peter Wolpert, CEO of Moberg Pharma.

About MOB-015 and nail fungus
MOB-015 is a new topical treatment for nail fungus with fungicidal, keratolytic
(removes dead cells from the skin's outermost layer) and emollient properties.
MOB-015 is based on Moberg Pharma's patent pending formulation technology, which
in preclinical studies has been shown to transport high concentrations of
terbinafine in and through nail tissue. As MOB-015 is applied locally, the side
effects associated with oral medications are avoided.

Nail fungus is the most common nail disease and afflicts approximately 10
percent of the population and is more common among the elderly. The market is
expected to exceed USD 1 billion. Many patients remain untreated and according
to specialists in the field, there is a great need for a new topical treatment
with a favorable side-effect profile.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.00 am (CET) on May 27, 2013.
For further information, please contact:
Peter Wolpert, CEO
Mobile: +46 (0)70 - 735 71 35
E-mail: peter.wolpert@mobergpharma.se (peter.wolpert@mobergderma.se)

Magnus Persson, IR
Mobile: +46 (0)73 - 355 26 01
E-mail: magnus.persson@mobergpharma.se (magnus.persson@mobergderma.se)
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
direct sales through its own sales organization in the US and sales through
distributors in more than 35 countries. The company’s product portfolio includes
topical products for the treatment of skin disorders and pain under the brands
Kerasal®, Jointflex®, Kerasal Nail® and Kaprolac®. Kerasal Nail® (Nalox™ in many
markets) is the leading product for the treatment of nail disorders in the
Nordic market. The portfolio is developed further through acquisitions and in
-licensing of products as well as product development with focus on innovative
drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm
and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap
list of the NASDAQ OMX Nordic Exchange Stockholm. For further information,
please visit: www.mobergpharma.se.